The author described retatrutide as a breakthrough in obesity treatment, saying that after 80 weeks, participants had lost an average of 25% of their weight, with less knee pain and fewer sleep apnea episodes. At a dose of 12 mg per week, weight loss was 28.3%, and 45.3% of participants lost at least 30% of their weight, the author wrote.

